mcc-950 has been researched along with Diabetes-Mellitus--Type-2* in 1 studies
1 other study(ies) available for mcc-950 and Diabetes-Mellitus--Type-2
| Article | Year |
|---|---|
Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis.
The NLRP3 inflammasome, which regulated a proinflammatory programmed cell death form termed pyroptosis, is involved in the pathological process of various human diseases, such as multiple sclerosis, type 2 diabetes, and gout. Thus, compounds inhibiting activation of the NLRP3 inflammasome can be promising treatments for these diseases. In this study, we conducted a phenotypic screening against NLRP3-dependent pyroptosis and discovered the hit compound 1, which showed moderate antipyroptotic activity. Chemistry efforts to improve potency of 1 resulted in a novel compound 59 (J114), which exhibited a half-maximal inhibitory concentration (IC Topics: Animals; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Inflammasomes; Interleukin-1beta; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Species Specificity | 2022 |